KBY Biotech Indexv0.0.34
Search
← Pipeline|ZEN-2386

ZEN-2386

Phase 3
By Zentiva
Source: Trial-derived·Trials: 2
Modality
Degrader
MOA
WRNi
Target
PCSK9
Pathway
Proteasome
Gastric CaFTDOCD
Development Pipeline
Preclinical
~Jul 2019
→ ~Oct 2020
Phase 1
~Jan 2021
→ ~Apr 2022
Phase 2
~Jul 2022
→ ~Oct 2023
Phase 3
Jan 2024
→ Jun 2028
Phase 3Current
NCT03531772
425 pts·FTD
2025-07→2027-09·Active
NCT08232783
1,431 pts·OCD
2024-01→2028-06·Not yet recruiting
1,856 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-09-191.5y awayPh3 Readout· FTD
2028-06-032.2y awayPh3 Readout· OCD
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P3
Not yet…
P3
Active
Catalysts
Ph3 Readout
2027-09-19 · 1.5y away
FTD
Ph3 Readout
2028-06-03 · 2.2y away
OCD
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT03531772Phase 3FTDActive425EFS
NCT08232783Phase 3OCDNot yet recr...1431UPCR
Competitors (10)
DrugCompanyPhaseTargetMOA
ABB-1817AbbViePhase 3SHP2WRNi
ZanusertibAbbVieApprovedPCSK9KRASG12Di
BMY-7975Bristol-Myers SquibbPhase 1MALT1WRNi
GSK-4334GSKPreclinicalCD47WRNi
AMG-2752AmgenPreclinicalMDM2WRNi
GIL-4361Gilead SciencesPreclinicalPCSK9STINGag
REG-7737RegeneronPreclinicalCD123WRNi
REG-2172RegeneronPhase 1/2PCSK9Anti-Tau
VRT-5853Vertex PharmaPhase 3AβWRNi
PemitapinarofBeiGeneApprovedKRASG12CWRNi